DELTA-FLY-PHARMA
Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.
A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States. Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.
DFP-14927 is an amide bond of DFP-10917 to a carboxylic acid at the end of polyethylene glycol (PEG) with a molecular weight of 40,000, and it is extremely stable in human blood after intravenous administration, allowing for weekly treatment regimen. DFP-14927 is a drug delivery system (DDS) with a mechanism that allows selective release of DFP-10917 into cancer tissues by amidolysis of proteases that are highly expressed in them.
Compared to high molecular weight antibody-drug conjugates (ADCs), medium-sized PEG covalent conjugates are known to have retention in blood vessels around cancer and cancer cell membranes and higher permeability into tumors, and therefore, the concentration of DFP-10917 in cancer tissue can be measured by conventional analysis without the use of radioisotope technology.
Soon after the expected effective concentration of DFP-10917 in cancer tissue is confirmed in the study, we plan to conduct an expanded Phase I study, equivalent to a Phase II clinical trial, in patients with colorectal cancer who have failed existing approved drugs.
The composition of matter patent for DFP-14927 has been granted in the United States, Europe, Asian countries and others, which will enable global marketing of DFP-14927.
In collaboration with leading oncology hospitals in the U.S., we are considering the development of DFP-14927 in haematological cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in addition to solid tumors.
For our future global development and marketing strategy, we are considering collaboration with a major global pharmaceutical company that has strength and expertise in the oncology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207063856/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $2,500,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC21.4.2025 23:00:00 CEST | Press release
Venture Global Inc. (“Venture Global”) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $2,500,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 7.50% senior secured notes due 2033 in an aggregate principal amount of $1,250,000,000 (the “2033 Notes”) and (ii) a series of 7.75% senior secured notes due 2035 in an aggregate principal amount of $1,250,000,000 (the “2035 Notes” and, together with the 2033 Notes, the “Notes”). The 2033 Notes will mature on May 1, 2033 and the 2035 Notes will mature on May 1, 2035. VGPL intends to use the net proceeds from the offering to (i) prepay certain amounts outstanding under VGPL’s existing senior secured first lien credit facilities (the “Existing Credit Facilities”) and (ii) pay fees and expenses in connection with the offering. The notes are guaranteed by Venture Global Gator Express, LLC (VGPL’s affiliate). The Notes are secur
Clearwater Analytics Finalizes Acquisition of Enfusion21.4.2025 22:15:00 CEST | Press release
Clearwater Will Deliver Industry’s First Unified, Cloud-Native Front-to-Back Platform for Institutional Investors Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the successful completion of its acquisition of Enfusion, Inc. (NYSE: ENFN), a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund sectors, in a deal valued at approximately $1.5 billion. This strategic combination positions Clearwater as the industry’s first single-instance, multi-tenant, cloud-native platform to unify front, middle, and back-office investment operations. By integrating portfolio and order management, IBOR, risk, accounting, and client reporting into one seamless solution, Clearwater is replacing the fragmented legacy model with a modern platform that empowers faster decision-making and operational clarity across asset classes and geographies. “The close of the Enfusion acquisition marks a major
Estithmar Holding Reports an Exceptional 50% Surge in Net Profit to QAR 170 Million21.4.2025 21:03:00 CEST | Press release
Announcing Q1 2025 Financial Results Estithmar Holding Q.P.S.C. announced a net profit of QAR 170 million for Q1 2025, reflecting a 50% increase compared to the same period last year. The company highlighted a 64% surge in revenue, reaching QAR 1.3 billion compared to QAR 797 million in Q1 2024. Gross profit rose to QAR 416 million, from QAR 196 million in Q1 2024. EBITDA reached QAR 273 million, marking a 53% increase. Earnings per share also grew by 57%, reaching QAR 0.047. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421669945/en/ Estithmar Holding Reports an Exceptional 50% Surge in Net Profit to QAR 170 Million (Infographic: AETOSWire) These strong financial indicators reflect the efficiency of Estithmar Holding’s investment strategy. International projects previously announced by Estithmar Holding started to have a tangible impact on its financial performance in revenue, profits and assets. The results reflect the
Leading Global Battery Expert Kenneth Hoffman to Join Pure Lithium as Special Advisor21.4.2025 16:52:00 CEST | Press release
Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announces that Kenneth Hoffman (CFA, CIM) will join the company as a Special Advisor, leveraging his vast experience across the battery value chain to advance our drive towards full commercialization. Mr. Hoffman, who was previously Global Head of Battery Materials at McKinsey, will be a crucial asset for Pure Lithium’s commercialization strategy and development of partnerships. Working directly with Pure Lithium CEO Emilie Bodoin, he will bring a deep understanding of batteries and a unique ability to connect market dynamics with operational decision making that will be invaluable for Pure Lithium. Pure Lithium Founder and CEO Emilie Bodoin said: “I feel very privileged to bring Ken aboard at this crucial time in Pure Lithium’s evolution. He is simply one of the leading experts on batteries, forming partnerships and developing successful businesses in energy storage. We
China’s Moutai Elevates Chinese Liquor Culture onto the Global Stage21.4.2025 15:59:00 CEST | Press release
China’s premier liquor brand Moutai captivated audiences with an impressive exhibition highlighting its global journey and the richness of Chinese liquor culture at the recently concluded 5th China International Consumer Products Expo (CICPE), or Hainan Expo 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421891944/en/ Moutai’s pavilion at the recently concluded 5th China International Consumer Products Expo in Haikou, China. Held in Haikou, the capital of South China's Hainan Province, the five-day event welcomed over 1,700 enterprises and 4,200 consumer brands from 71 countries and regions. From technology and jewelry to gourmet food and Chinese lifestyle products, the Expo served as a vibrant showcase of global consumer trends. On this international stage, Moutai stood out as a symbol of Eastern elegance. Under the theme “Share Open Opportunities, Co-create a Better Life,” the brand spotlighted the cultural signif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom